Lia Gore

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Long-term survival after intralesional resection and multi-modal therapy of thoracic spine osteosarcoma
    Lia Gore
    Section of Pediatric Hematology/Oncology, University of Colorado Health Sciences Center, Colorado, USA
    Med Pediatr Oncol 40:400-2. 2003
  2. ncbi Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
    Lia Gore
    Section of Hematology Oncology BMT, Department of Pediatrics, University of Colorado School of Medicine and The Children s Hospital, Denver, CO, USA
    Semin Oncol 34:S35-9. 2007
  3. ncbi A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
    Lia Gore
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Clin Cancer Res 14:4517-25. 2008
  4. ncbi A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
    L Gore
    Department of Pediatrics, Medical Oncology, and Pharmacology, University of Colorado Cancer Center, Aurora, CO, USA
    Ann Oncol 17:1709-17. 2006
  5. ncbi A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
    Laura Q M Chow
    University of Colorado Heath Sciences Center, Aurora, CO, USA
    Cancer Chemother Pharmacol 63:65-74. 2008
  6. ncbi A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Christopher Lieu
    University of Colorado Cancer Center, 1665 North Ursula Street, Aurora, CO, USA
    Invest New Drugs 27:53-62. 2009
  7. ncbi A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
    Laura Q M Chow
    University of Colorado Cancer Center, Aurora, CO, USA
    Cancer Chemother Pharmacol 62:631-46. 2008
  8. ncbi Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
    Stephen Leong
    Division of Medical Oncology, University of Colorado Health Sciences Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 27:4413-21. 2009
  9. ncbi A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
  10. ncbi Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability
    Lia Gore
    Division of Pediatric Hematology Oncology Bone Marrow Transplant, Children s Hospital and The University of Colorado Denver, Aurora, Colorado, USA
    Pediatr Blood Cancer 52:242-7. 2009

Collaborators

Detail Information

Publications22

  1. ncbi Long-term survival after intralesional resection and multi-modal therapy of thoracic spine osteosarcoma
    Lia Gore
    Section of Pediatric Hematology/Oncology, University of Colorado Health Sciences Center, Colorado, USA
    Med Pediatr Oncol 40:400-2. 2003
  2. ncbi Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
    Lia Gore
    Section of Hematology Oncology BMT, Department of Pediatrics, University of Colorado School of Medicine and The Children s Hospital, Denver, CO, USA
    Semin Oncol 34:S35-9. 2007
    ..We hypothesize that forodesine contributed to a primary anti-leukemic cytotoxic effect as well as a secondary immunologic effect by allowing the development of an ongoing graft-versus-leukemia effect in these patients...
  3. ncbi A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
    Lia Gore
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Clin Cancer Res 14:4517-25. 2008
    ....
  4. ncbi A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
    L Gore
    Department of Pediatrics, Medical Oncology, and Pharmacology, University of Colorado Cancer Center, Aurora, CO, USA
    Ann Oncol 17:1709-17. 2006
    ..To evaluate the toxicity and pharmacological and biological properties of the farnesyl protein transferase (FPTase) inhibitor, tipifarnib (R115777, ZARNESTRAtrade mark) and capecitabine administered for 14 days every 3 weeks...
  5. ncbi A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
    Laura Q M Chow
    University of Colorado Heath Sciences Center, Aurora, CO, USA
    Cancer Chemother Pharmacol 63:65-74. 2008
    ..This study evaluated the safety, toxicity, pharmacological properties and biological activity of PI-88, a heparanase endoglycosidase enzyme inhibitor, with fixed weekly docetaxel in patients with advanced solid malignancies...
  6. ncbi A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Christopher Lieu
    University of Colorado Cancer Center, 1665 North Ursula Street, Aurora, CO, USA
    Invest New Drugs 27:53-62. 2009
    ..To evaluate the toxicity, pharmacological, and biological properties of the combination of bortezomib, etoposide, and carboplatin in adults with advanced solid malignancies...
  7. ncbi A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
    Laura Q M Chow
    University of Colorado Cancer Center, Aurora, CO, USA
    Cancer Chemother Pharmacol 62:631-46. 2008
    ....
  8. ncbi Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study
    Stephen Leong
    Division of Medical Oncology, University of Colorado Health Sciences Center, 12801 E 17th Ave, Aurora, CO 80045, USA
    J Clin Oncol 27:4413-21. 2009
    ....
  9. ncbi A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
    ..i.d.) on days 1-14 every 21 days. Further disease-directed studies are warranted, such as in malignancies in the treatment of which both capecitabine and inhibitors of angiogenesis have previously been benchmarked as being effective...
  10. ncbi Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability
    Lia Gore
    Division of Pediatric Hematology Oncology Bone Marrow Transplant, Children s Hospital and The University of Colorado Denver, Aurora, Colorado, USA
    Pediatr Blood Cancer 52:242-7. 2009
    ..The neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents...
  11. ncbi A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors
    Michele Basche
    University of Colorado Cancer Center, Aurora, Colorado 80010, USA
    Clin Cancer Res 12:5471-80. 2006
    ..CONCLUSION: The recommended dose of PI-88 administered for 4 consecutive days bimonthly or weekly is 250 mg/d. PI-88 was generally well tolerated. Evidence of efficacy in melanoma supports further evaluation of PI-88 in phase II trials...
  12. ncbi Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents
    Margaret E Macy
    Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver, 13123 East 16th Avenue B 115, Aurora, CO 80045, USA
    Invest New Drugs 30:468-79. 2012
    ..Taken together, these preclinical data support clinical evaluation of vandetanib, in combination with cytotoxic chemotherapy, for pediatric leukemia...
  13. ncbi Entinostat for treatment of solid tumors and hematologic malignancies
    Jeffrey Knipstein
    Instructor in Pediatrics, The University of Colorado School of Medicine, Department of Pediatrics and Children s Hospital Colorado, Center for Cancer and Blood Disorders, Box B115 TCH, 13123 East 16th Avenue, Aurora, CO 80045, USA
    Expert Opin Investig Drugs 20:1455-67. 2011
    ..Future clinical trials will likely focus on its use in combination with other agents that are able to exploit the epigenetic changes rendered by deacetylase inhibition...
  14. ncbi A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
    Qing Zhou
    Developmental Therapeutics Program, Division of Medical Oncology, University of Colorado, Aurora, CO 80045, USA
    Invest New Drugs 29:340-6. 2011
    ..This first-in-human phase I study evaluated the tolerability, pharmacokinetics and preliminary evidence of activity of ENMD-1198 in advanced cancer patients...
  15. ncbi PARP1 expression in pediatric central nervous system tumors
    Valerie N Barton
    Department of Pediatrics, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA
    Pediatr Blood Cancer 53:1227-30. 2009
    ..Poly(ADP-ribose) polymerase-1 (PARP1) is a DNA repair protein that has been studied in a variety of malignancies and may interfere with therapy-induced DNA damage, however expression in pediatric CNS tumors is unknown...
  16. ncbi MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma
    Andrew M Donson
    University of Colorado at Denver and Health Sciences Center and Denver Children s Hospital, Denver, Colorado, USA
    Pediatr Blood Cancer 48:403-7. 2007
    ..We explored MGMT promoter methylation in pediatric GBM and its relationship to survival and temozolomide sensitivity...
  17. ncbi Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
    Alisa B Lee-Sherick
    Department of Paediatrics, Section of Haematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver School of Medicine, Aurora, CO, USA
    Br J Haematol 151:295-311. 2010
    ..This article explores many of the potential targeted therapies in varying stages of development, from those currently in clinical trials to those still being refined in the research laboratory...
  18. ncbi Cord blood transplant in childhood ALL
    Kelly K Sawczyn
    The Children's Hospital, Denver, Colorado, USA
    Pediatr Blood Cancer 45:964-70. 2005
    ..CONCLUSIONS: We conclude that CBT can effectively treat ALL in children with high risk features and following relapse...
  19. ncbi Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates
    Julie Kanter
    Department of Pediatrics, Washington University, St Louis, Missouri, USA
    Clin Cancer Res 14:3942-7. 2008
    ....
  20. ncbi Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study
    Rochelle Bagatell
    Department of Pediatrics and Steele Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    Clin Cancer Res 13:1783-8. 2007
    ....
  21. ncbi Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Alex A Adjei
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:2139-46. 2008
    ..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer...
  22. ncbi Dynamic and modern: bringing the ethics of phase I trials up to date
    D Ross Camidge
    J Clin Oncol 24:5178-9; author reply 5179-80. 2006